Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ovid Therapeutics Inc. - Common Stock
(NQ:
OVID
)
2.620
+0.320 (+13.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ovid Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
March 18, 2026
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
March 18, 2026
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Participate in Upcoming Investor Conferences
February 25, 2026
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
December 18, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
December 02, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
November 12, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
October 03, 2025
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued...
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
October 03, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
August 13, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
July 23, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
June 25, 2025
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
June 05, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
May 13, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
April 02, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
March 03, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
December 02, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
November 12, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Host Investor Event
October 31, 2024
KCC2 Download Day on Wednesday, November 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
September 26, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
September 11, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at Upcoming September Investor Conferences
September 04, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
August 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
August 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
August 01, 2024
From
The Schall Law Firm
Via
Business Wire
Ovid Therapeutics to Present at Upcoming August Investor Conferences
July 30, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
July 23, 2024
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
July 10, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
